ORM Ormeloxifene (Centchroman)
Description: <p><b>Ormeloxifene (Centchroman)</b> — Nonsteroidal selective estrogen receptor modulator (SERM) originally developed as a once-weekly oral contraceptive. Ormeloxifene exhibits tissue-selective estrogenic and anti-estrogenic effects, including strong anti-estrogenic activity in breast tissue and modulation of estrogen signaling in the endometrium.</p>
<p><b>Drug class:</b> Selective Estrogen Receptor Modulator (SERM) / nonsteroidal anti-estrogen / repurposed anticancer drug.</p>
<p><b>Primary clinical uses:</b> Oral contraception, mastalgia, fibroadenoma, and selected gynecologic disorders. Ormeloxifene has been used clinically in India for decades.</p>
<p><b>Cancer relevance:</b> Moderate to strong preclinical evidence with limited clinical evidence. Ormeloxifene has demonstrated antiproliferative, pro-apoptotic, anti-invasive, and antimetastatic effects in breast, ovarian, head-and-neck, pancreatic, prostate, and hematologic cancer models. Early clinical studies in advanced breast cancer also reported objective responses in a subset of patients.</p>
<p><b>Typical mechanisms:</b> Estrogen receptor signaling modulation; proliferation ↓; cell-cycle progression ↓; apoptosis ↑; BAX ↑; BCL2 ↓; caspase activation ↑; PI3K/AKT signaling ↓; MAPK/ERK signaling ↓; NF-kB signaling ↓; migration ↓; invasion ↓; EMT ↓. Mechanisms vary by tumor type and may include estrogen-receptor-independent effects.</p>
<p><b>Estrogen receptor relevance:</b> Ormeloxifene is a SERM rather than a pure estrogen receptor antagonist. Its effects are tissue-selective and should not be interpreted as universal ESR1/ESR2 inhibition.</p>
<p><b>Pharmacokinetics:</b> Ormeloxifene has a long elimination half-life, approximately 168 hours, supporting once-weekly contraceptive dosing.</p>
<p><b>Recommended product classification:</b> Drug — SERM / Repurposed Anticancer Drug.</p>